Trastuzumab Should Remain Standard Of Care For HER2-Positive Breast Cancer

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces clinical trial findings showing that trastuzumab (Herceptin) should remain the standard of care for this cancer. read more

Read the whole article on

More from